The present narrative review comprehensively examined the existing studies investigating the use of the novel incretin analogs semaglutide and tirzepatide in patients with T1D (as non-insulin adjunct therapies at different stages of the disease) and in patients with LADA. Here, INS is linked to type 1 diabetes mellitus.